Daniel Turkewitz, Publication Development Partner at Taylor & Francis Group, shared on LinkedIn:
“Thrilled to share my latest article with Oncology Central: ‘Radiopharmaceutical therapy delays metastatic prostate cancer disease progression when given earlier’
This article highlights research from the PSMAddition Phase III trial, showing that adding 177Lu-PSMA-617 to standard therapy at diagnosis reduced disease progression risk by 28% in patients with PSMA-positive metastatic prostate cancer.
This represents a significant advance for patients who previously had to wait until their cancer progressed before accessing this targeted treatment. The early intervention approach offers meaningful advantages, extending radiographic progression-free survival while maintaining a manageable safety profile.
As Dr. Scott Tagawa noted, “Now our patients can get 177Lu-PSMA-617 at diagnosis and don’t have to wait until they develop resistance to the backbone therapies.”
Title: Radiopharmaceutical therapy delays metastatic prostate cancer disease progression when given earlier
Author: Daniel Turkewitz
Read the Full Article
You can also read: ‘PSMAddition: [177Lu]Lu-PSMA-617 Improves Radiographic PFS in PSMA-Positive mAPMN/S Prostate Cancer‘
